Davi Tanajura Costa

Dr. Davi Tanajura Costa

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Expert Review of Vaccines
Verified
Journal Article
Closed access
IVIrineu Dos Santos Viana
Irineu Dos Santos Viana
MSMaria Luísa Cordeiro Santos
Maria Luísa Cordeiro Santos
HMHanna Santos Marques
Hanna Santos Marques
VGVinícius Lima de Souza Gonçalves
Vinícius Lima de Souza Gonçalves
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FMFabrício De melo
Fabrício De melo
Introduction: The interest of the world scientific community for an effective vaccine against Helicobacter pylori infection arises from its high prevalence and association with many diseases. Moreover, with an immunological response that is not always effective for the eradication of the bacteria and an increasing antibiotic resistance in the treatment of this infection, the search for a vaccine and new therapeutic modalities to control this infection is urgent. Areas covered: We bring an overview of the infection worldwide, discussing its prevalence, increasing resistance to antibiotics used in its therapy, in addition to the response of the immune system to the infection registered so far. Moreover, we address the most used antigens and their respective immunological responses expected or registered up to now. Finally, we address the trials and their partial results in development for such vaccines. Expert opinion: Although several studies for the development of an effective vaccine against this pathogen are taking place, many are still in the preclinical phase or even without updated information. In this sense, taking into account the high prevalence and association with important comorbidities, the interest of the pharmaceutical industry in developing an effective vaccine against this pathogen is questioned.

1 May 2010 in Urology
Verified
Journal Article
Closed access
POPaulo Oliveira
Paulo Oliveira
NCNéviton M. Castro
Néviton M. Castro
AMAndré L. Muniz
André L. Muniz
DCDavi Tanajura Costa
Davi Tanajura Costa
JBJulio C. Brandão
Julio C. Brandão
Edgar M CarvalhoEdgar M Carvalho
Edgar M Carvalho

19 September 2012 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SSSilvane Braga Santos
Silvane Braga Santos
POPaulo Oliveira
Paulo Oliveira
TLTania Luna
Tania Luna
ASAnselmo Souza
Anselmo Souza
MNMárcia Nascimento
Márcia Nascimento
Edgar M CarvalhoEdgar M Carvalho
Edgar M Carvalho

1 October 2012 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
ASAnselmo Souza
Anselmo Souza
DCDavi Tanajura Costa
Davi Tanajura Costa
CTCristina Toledo-Cornell
Cristina Toledo-Cornell
SSSilvane Santos
Silvane Santos
Edgar M CarvalhoEdgar M Carvalho
Edgar M Carvalho
The human T lymphotropic virus type-1 (HTLV-1) was the first human retrovirus identified. The virus is transmitted through sexual intercourse, blood transfusion, sharing of contaminated needles or syringes and from mother to child, mainly through breastfeeding. In addition to the well-known association between HTLV-1 and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), several diseases and neurologic manifestations have been associated with the virus. This review was conducted through a PubMed search of the terms HTLV-1, immune response and neurological diseases. Emphasis was given to the most recent data regarding pathogenesis and clinical manifestations of HTLV-1 infection. The aim of the review is to analyze the immune response and the variety of neurological manifestations associated to HTLV-1 infection. A total of 102 articles were reviewed. The literature shows that a large percentage of HTLV-1 infected individuals have others neurological symptoms than HAM/TSP. Increased understanding of these numerous others clinical manifestations associated to the virus than adult T cell leukemia/lymphoma (ATLL) and HAM/TSP has challenged the view that HTLV-1 is a low morbidity infection.

1 March 2019 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
AMAimée Teixeira dos Santos Meira
Aimée Teixeira dos Santos Meira
DCDavi Tanajura Costa
Davi Tanajura Costa
IVIrineu dos Santos Viana
Irineu dos Santos Viana
BACKGROUND: The gastroesophageal reflux disease (GERD) is the most common esophageal disease in medical practice, and it is suspected according to patients’ symptoms. GERD can be classified in erosive esophagitis (EE) according to the presence of upper gastrointestinal endoscopy findings. OBJECTIVE: To evaluate endoscopic findings in patients with symptoms suggestive of GERD comparing epicemiological and risk factors. METHODS: Upper endoscopy reports were examined retrospectively from patients with symptoms of GERD such as heartburn, regurgitation, cough, throat clearing, globus and chest pain. EE was determined based on Los Angeles classification. Comparisons between risk factors in EE and non-EE groups were done with statistical analysis. RESULTS: A total of 984 endoscopic reports were examined and 676 selected for analysis (281 with EE and 395 with non-EE form). Most were female 381 (56.36%) with a mean age of 44.01±15.40 years. Hiatal hernia was present in 47(6.96%) and smoking in 41(6.07%). Univariate logistic regression showed that male (OR=2.24, CI 95%, 1.63-3.06) and hiatal hernia (OR=4.52, CI 95%, 2.30-8.89) were independent predictors of erosions in the EE group. The presence of hiatal hernia (OR=12.04, CI 95%, 3.57-40.62), smoking (OR=8.46, CI 95%, 3.28-31.32) and aged patients (OR=8.01, CI 95%, 2.42-26.49) were also indicated as a risk factor for severe EE (grades C and D of Los Angeles). CONCLUSION Male gender and hiatal hernia were associated with EE. Aged patients, smoking and hiatal hernia were related to severe EE. It is suggested that the risk factors for EE and non-EE types are different. Cohort studies are necessary to identify the exact mechanisms involved in each disease form.

1 March 2012 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MSMichael A. Sundberg
Michael A. Sundberg
DCDavi Tanajura Costa
Davi Tanajura Costa
GOGloria Orge
Gloria Orge
NCNéviton M. Castro
Néviton M. Castro
AMAndré Muniz
André Muniz
ECEdgar M. Carvalho
Edgar M. Carvalho